Yu-Bin Wang1, Cai-Feng Ba. 1. Department of General Surgery, The First Affiliated Hospital, Liaoning Medical University, China.
Abstract
BACKGROUND/AIMS: To observe the promoter methylation of esophageal cancer-related gene 4 (ECRG4) in gastric cancer tissues and explore its clinical significance. METHODOLOGY: ECRG4 promoter methylation was detected with methylation-specific PCR in 49 samples of gastric cancer tissues, 30 samples of peri-cancerous tissues and 15 samples of normal tissues. The relations of ECRG4 promoter methylation to pathology, age, gender and lymph node metastasis were analyzed. RESULTS: The rate of ECRG4 promoter methylation was higher in gastric cancer tissues (69.4% (34/49)) and peri-cancerous tissues (53.3% (16/30)) than in normal tissues (6.7% (1/15)) (p<0.01). The rate of ECRG4 promoter methylation was higher in stage III+IV (80% (24/30)) than in stage I+II gastric cancer tissues (52.6% (10/19)) (p<0.05). The rate of ECRG4 promoter methylation was not related to age, gender and lymph node metastasis (all p>0.05). CONCLUSIONS: Aberrant ECRG4 promoter methylation may be used to monitor early gastric cancer and predict pathological staging. ECRG4 may become a molecular therapeutic target against gastric cancer.
BACKGROUND/AIMS: To observe the promoter methylation of esophageal cancer-related gene 4 (ECRG4) in gastric cancer tissues and explore its clinical significance. METHODOLOGY:ECRG4 promoter methylation was detected with methylation-specific PCR in 49 samples of gastric cancer tissues, 30 samples of peri-cancerous tissues and 15 samples of normal tissues. The relations of ECRG4 promoter methylation to pathology, age, gender and lymph node metastasis were analyzed. RESULTS: The rate of ECRG4 promoter methylation was higher in gastric cancer tissues (69.4% (34/49)) and peri-cancerous tissues (53.3% (16/30)) than in normal tissues (6.7% (1/15)) (p<0.01). The rate of ECRG4 promoter methylation was higher in stage III+IV (80% (24/30)) than in stage I+II gastric cancer tissues (52.6% (10/19)) (p<0.05). The rate of ECRG4 promoter methylation was not related to age, gender and lymph node metastasis (all p>0.05). CONCLUSIONS: Aberrant ECRG4 promoter methylation may be used to monitor early gastric cancer and predict pathological staging. ECRG4 may become a molecular therapeutic target against gastric cancer.
Authors: Todd W Costantini; Raul Coimbra; Nicole E Lopez; Jeanne G Lee; Bruce Potenza; Alan Smith; Andrew Baird; Brian P Eliceiri Journal: Surg Infect (Larchmt) Date: 2015-10-13 Impact factor: 2.150
Authors: Sonia Podvin; Miles C Miller; Ryan Rossi; Jasmine Chukwueke; John E Donahue; Conrad E Johanson; Andrew Baird; Edward G Stopa Journal: JSM Alzheimers Dis Relat Dement Date: 2016-04-01